Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NITRO-BID vs IMDUR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Prophylaxis of angina pectoris,Treatment of acute angina attacks,Off-label: acute myocardial infarction (limited use), heart failure with pulmonary edema (if not hypotensive)
Prevention of angina pectoris due to coronary artery disease,Off-label: chronic heart failure (as adjunctive therapy), esophageal spasm
Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
Terminal half-life of nitroglycerin is 1-4 minutes; clinical effects are short-lived due to rapid redistribution and metabolism.
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Rapidly metabolized via hepatic glutathione-organic nitrate reductase to dinitrates and mononitrates; also metabolized in erythrocytes and vascular tissue.
Primarily hepatic metabolism via denitration and glucuronidation; isosorbide mononitrate is the active metabolite of isosorbide dinitrate and does not undergo significant first-pass metabolism.
Renal: <1% unchanged; extensive metabolism followed by renal excretion of metabolites, with minor biliary/fecal elimination (<5%).
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Approximately 60% bound to plasma proteins (mainly albumin).
Less than 5%, primarily to albumin. Very low protein binding, which contributes to high free fraction.
Vd approximately 3.3 L/kg, indicating extensive distribution into tissues beyond plasma volume.
Volume of distribution is approximately 0.6-0.7 L/kg for isosorbide mononitrate. This moderate Vd indicates distribution into total body water and some tissue binding.
Sublingual: ~40% (high first-pass hepatic metabolism); Transdermal: ~72% (bypasses first-pass); Oral: <10% due to extensive hepatic metabolism.
Oral bioavailability is nearly 100% for isosorbide mononitrate due to lack of first-pass metabolism (unlike isosorbide dinitrate). For IMDUR extended-release, relative bioavailability is comparable to immediate-release, with controlled release properties.
No specific adjustment required; nitroglycerin is minimally renally excreted.
No dosage adjustment required for GFR ≥30 m L/min. For GFR <30 m L/min, use with caution; consider starting at 30 mg once daily and titrate slowly.
Child-Pugh A: no adjustment. Child-Pugh B: consider dose reduction (25-50% of normal dose). Child-Pugh C: avoid or use with extreme caution; reduce dose by 50% or more.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%; start at 30 mg once daily. Child-Pugh Class C: Contraindicated or use with extreme caution; start at 30 mg once daily with careful monitoring.
Not routinely recommended; limited data. Intravenous: start at 0.25-0.5 mcg/kg/min, titrate by 0.5-1 mcg/kg/min every 3-5 min to effect; max 5 mcg/kg/min.
Not approved for pediatric use. Limited data: 0.5-2 mg/kg orally once daily, not to exceed 120 mg once daily.
Start at lower end of dosing range due to increased sensitivity and risk of hypotension. Sublingual: 0.3 mg initial. Transdermal: 0.2 mg/hour initially.
Start at 30 mg once daily; titrate slowly due to increased sensitivity and risk of hypotension.
No FDA boxed warning specifically for NITRO-BID. However, nitroglycerin is contraindicated with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to severe hypotension.
Not recommended for use in patients with acute myocardial infarction (MI) or congestive heart failure (CHF) requiring rapid hemodynamic monitoring; use only under close clinical observation.
May cause severe hypotension, especially with volume depletion; avoid in patients with hypertrophic cardiomyopathy; use caution in hepatic/renal impairment; tolerance develops with chronic use; may aggravate angina when discontinuing abruptly.
Hypotension: may cause severe hypotension, especially with upright posture,Tolerance: continuous use may lead to tolerance and cross-tolerance to other nitrates; use with a daily nitrate-free interval,Headache: often occurs but may diminish with continued use,Glaucoma: controversial; generally considered safe,Volume depletion: increased risk of hypotension
Hypersensitivity to nitrates; concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil); severe anemia; increased intracranial pressure; circulatory failure or shock; right ventricular infarction; constrictive pericarditis; cardiac tamponade.
Hypersensitivity to isosorbide mononitrate or other nitrates,Concurrent use with phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil, vardenafil) due to risk of severe hypotension,Severe anemia,Increased intracranial pressure (e.g., head trauma, cerebral hemorrhage),Acute circulatory failure or shock
Avoid alcohol as it may cause hypotension. No specific food interactions; maintain usual diet.
Avoid high-fat meals as they may delay absorption. No specific food interactions; alcohol may increase hypotensive effects.
Pregnancy Category C. Animal studies have shown fetal harm (bradycardia, reduced birth weight). Inadequate human data for first trimester; avoid unless benefit outweighs risk. Second and third trimesters: associated with maternal hypotension and fetal bradycardia; use only if clearly needed.
FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to the fetus. First trimester: No specific malformation pattern identified. Second and third trimesters: Potential risk of fetal hypotension and reduced placental perfusion due to maternal vasodilation.
Excreted in breast milk in small amounts; M/P ratio approximately 0.5. Although risk to infant appears low, caution is advised. Monitor infant for hypotension, methemoglobinemia (rare).
Unknown if isosorbide mononitrate is excreted in human breast milk. M/P ratio not established. Caution advised; consider discontinuing nursing or drug, balancing importance of drug to mother.
No formal dose adjustment studies in pregnancy. Pharmacokinetic changes (increased plasma volume, altered protein binding) may require upward titration. Start at lowest effective dose and titrate based on maternal hemodynamic response (BP, HR). Avoid maternal hypotension (systolic <100 mm Hg).
No specific dose adjustments recommended for pregnancy; however, hemodynamic changes (increased plasma volume, cardiac output) may alter pharmacokinetics. Start at lowest effective dose and titrate based on maternal response and tolerability.
NITRO-BID (nitroglycerin ointment) is used for prophylaxis of angina pectoris. Apply to hairless skin, preferably chest or upper arm. Rotate sites to avoid irritation. Do not rub in; spread thin layer. Tolerance develops with continuous use; remove at bedtime to provide nitrate-free interval. Avoid in patients with severe hypotension, hypertrophic obstructive cardiomyopathy, or concurrent use of phosphodiesterase-5 inhibitors (e.g., sildenafil).
Imdur (isosorbide mononitrate) is an extended-release nitrate used for angina prophylaxis. Avoid concomitant use with phosphodiesterase-5 inhibitors (e.g., sildenafil) due to risk of severe hypotension. Tachyphylaxis can occur with continuous use; maintain a daily nitrate-free interval (typically 10-12 hours) to preserve efficacy. Do not crush or chew extended-release tablets. Monitor blood pressure and heart rate during initiation. Use with caution in patients with hypertrophic obstructive cardiomyopathy, aortic stenosis, or volume depletion.
Apply the prescribed amount to skin, do not rub in.,Wash hands after application.,Rotate application sites to prevent skin irritation.,Remove the ointment at bedtime to prevent tolerance.,Store at room temperature away from heat and open flame.,Seek emergency care if chest pain persists after use.
Take Imdur exactly as prescribed, usually once daily in the morning to maintain a nitrate-free interval.,Do not crush, chew, or cut the tablet; swallow it whole with a glass of water.,Avoid taking erectile dysfunction medications (e.g., Viagra, Cialis, Levitra) while on Imdur, as this can cause a dangerous drop in blood pressure.,If you experience headache, it may indicate the drug is working; acetaminophen can help. Inform your doctor if headaches persist.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NITRO-BID vs IMDUR, answered by our medical review team.
NITRO-BID is a Nitrate Vasodilator that works by Nitroglycerin is a nitrate that relaxes vascular smooth muscle by conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cyclic guanosine monophosphate (c GMP) levels, leading to vasodilation. Primarily dilates veins, reducing preload and myocardial oxygen demand; also dilates coronary arteries.. IMDUR is a Nitrate Vasodilator that works by Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing c GMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NITRO-BID and IMDUR depend on the specific clinical indication. These are both Nitrate Vasodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NITRO-BID is: Sublingual: 0.3-0.6 mg at onset of angina, may repeat every 5 minutes up to 3 doses. Transdermal: 0.2-0.8 mg/hour patch applied daily for 12-14 hours, then removed for 10-12 hours.. The standard adult dose of IMDUR is: Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NITRO-BID and IMDUR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NITRO-BID is classified as Category C. Pregnancy Category C. Animal studies have shown fetal harm (bradycardia, reduced birth weight). Inadequate human data for first trimester; avoid unless benefit outweighs risk. Seco. IMDUR is classified as Category C. FDA Pregnancy Category C. In animal studies, isosorbide mononitrate (IMDUR) caused embryotoxicity and fetotoxicity at high doses. There are no adequate and well-controlled studies . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.